Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
13.57 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 78.637 | 105.762 | 181.564 | 114.634 | 207.136 | 147.84 | 90.483 | 16.875 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 78.637 | 105.762 | 181.564 | 114.634 | 207.136 | 147.84 | 90.483 | 16.875 |
| Net Receivables
| 22.454 | 12.531 | 7.712 | 0.8 | 0 | 0 | 0 | 0 |
| Inventory
| 5.065 | 6.702 | 5.512 | -0.8 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 4.955 | 5.452 | 7.473 | 7.729 | 4.819 | 3.661 | 0.84 | 0.358 |
| Total Current Assets
| 111.111 | 130.447 | 202.261 | 122.363 | 211.955 | 151.532 | 91.355 | 17.261 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 1.636 | 2.343 | 5.689 | 6.394 | 4.041 | 0.205 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 2.631 | 2.986 | 1.663 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 2.631 | 2.986 | 1.663 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 12.491 | 5.68 | 3.17 | 3.29 | 0.37 | 0.187 | 0.772 | 0 |
| Total Non-Current Assets
| 16.758 | 11.009 | 10.522 | 9.684 | 4.411 | 0.392 | 0.772 | 0 |
| Total Assets
| 127.869 | 141.456 | 212.783 | 132.047 | 216.366 | 151.924 | 92.127 | 17.261 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 6.06 | 14.175 | 13.552 | 9.372 | 8.52 | 5.872 | 5.909 | 2.227 |
| Short Term Debt
| 0.902 | 0.868 | 1.783 | 1.966 | 0.516 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 13.166 | 13.241 | 12.54 | 8.197 | 4.55 | 3.251 | 2.016 | 0.748 |
| Total Current Liabilities
| 20.128 | 28.284 | 27.875 | 19.535 | 13.586 | 9.123 | 7.925 | 2.975 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 0.517 | 0.899 | 1.851 | 2.013 | 1.714 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 6.239 | 3.052 | 2.951 | 4.663 | 2.163 | 2.274 | 2.05 | 2.225 |
| Total Non-Current Liabilities
| 6.756 | 3.951 | 4.802 | 6.676 | 3.877 | 2.274 | 2.05 | 2.225 |
| Total Liabilities
| 26.884 | 32.235 | 32.677 | 26.211 | 17.463 | 11.397 | 9.975 | 5.2 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.003 | 0.003 | 0.002 |
| Retained Earnings
| -457.47 | -436.043 | -340.475 | -285.2 | -165.863 | -84.835 | -41.561 | -22.4 |
| Accumulated Other Comprehensive Income/Loss
| 0.449 | 1.331 | 1.371 | -0.526 | 0.05 | 0.007 | -0.169 | 0.03 |
| Other Total Stockholders Equity
| 558.002 | 543.929 | 519.206 | 391.558 | 364.712 | 225.352 | 123.879 | 34.429 |
| Total Shareholders Equity
| 100.985 | 109.221 | 180.106 | 105.836 | 198.903 | 140.527 | 82.152 | 12.061 |
| Total Equity
| 100.985 | 109.221 | 180.106 | 105.836 | 198.903 | 140.527 | 82.152 | 12.061 |
| Total Liabilities & Shareholders Equity
| 127.869 | 141.456 | 212.783 | 132.047 | 216.366 | 151.924 | 92.127 | 17.261 |